Utidelone and bevacizumab for lung cancer with brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, utidelone and bevacizumab, for people with a type of lung cancer (non-squamous non-small cell) that has spread to the brain. The goal is to see if this treatment can shrink tumors in the brain and elsewhere.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Have non-squamous non-small cell lung cancer (adenocarcinoma type) that has spread to the brain
- Have brain tumors that are stable and do not need immediate radiation or surgery
- Have tried or cannot tolerate standard first-line treatment (chemotherapy and immunotherapy)
- Have good overall health (ECOG score 0 or 1) and adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
Hear when a new Non-small Cell Lung Cancer Patients with Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.